Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
| ▸ | ICMT | O60725 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008743 | 0.89 | PLA2G2A (0.70) | PLA2G2AICMTALDH1A1LMNAPPARD | |
| SCHEMBL2004159 | 0.85 | PLA2G2A (0.81) | PLA2G2AICMTALDH1A1LMNAPPARD | |
| SCHEMBL13802401 | 0.83 | PPARD (0.69) | PLA2G2AICMTAKR1C3PPARDPPARG | |
| SCHEMBL2005762 | 0.81 | PLA2G2A (0.70) | PLA2G2AICMTALDH1A1LMNAPPARD | |
| SCHEMBL2008179 | 0.80 | PLA2G2A (0.58) | PLA2G2AICMTALDH1A1LMNAAKR1C3 | |
| SCHEMBL2002884 | 0.79 | PLA2G2A (0.56) | PLA2G2AALDH1A1LMNAPPARDPPARG | |
| SCHEMBL8183003 | 0.79 | ALDH1A1 (0.56) | PLA2G2AICMTALDH1A1LMNAPPARD | |
| SCHEMBL9585816 | 0.78 | ICMT (0.56) | PLA2G2AICMTALDH1A1LMNAPPARD | |
| SCHEMBL8178374 | 0.77 | HTR6 (0.62) | ICMTALDH1A1LMNA | |
| SCHEMBL20769719 | 0.76 | ALDH1A1 (0.65) | PLA2G2AICMTALDH1A1LMNAAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PLA2G2A 409/4885ICMT 2891/4885ALDH1A1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.